Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study ; volume:103 ; number:6 ; day:13 ; month:3 ; year:2024 ; pages:1931-1940 ; date:6.2024
Annals of hematology ; 103, Heft 6 (13.3.2024), 1931-1940, 6.2024
- Urheber
-
Palandri, F.
Auteri, G.
Abruzzese, E.
Caocci, G.
Bonifacio, M.
Mendicino, F.
Latagliata, R.
Iurlo, A.
Branzanti, F.
Garibaldi, B.
Trawinska, M. M.
Cattaneo, D.
Krampera, M.
Mulas, O.
Martino, E. A.
Cavo, M.
Vianelli, N.
Impera, S.
Efficace, F.
Heidel, F.
Breccia, M.
Elli, E. M.
Palumbo, G. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-024-05704-0
- URN
-
urn:nbn:de:101:1-2407222101124.836202779833
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Palandri, F.
- Auteri, G.
- Abruzzese, E.
- Caocci, G.
- Bonifacio, M.
- Mendicino, F.
- Latagliata, R.
- Iurlo, A.
- Branzanti, F.
- Garibaldi, B.
- Trawinska, M. M.
- Cattaneo, D.
- Krampera, M.
- Mulas, O.
- Martino, E. A.
- Cavo, M.
- Vianelli, N.
- Impera, S.
- Efficace, F.
- Heidel, F.
- Breccia, M.
- Elli, E. M.
- Palumbo, G. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis